
    
      The study enroll a large population of approximately 252467 participants. The study would
      analyze association of cancer and pioglitazone in 2 cohorts based on the usage of
      pioglitazone. Participants in were originally planned to be followed-up from January 1, 1997
      to December 31, 2005. Based on the discussion with advisory board, it was recommended to
      increase the study population and duration of follow-up. The follow-up period was extended to
      June 30, 2012 for the study.

      This multi-center trial was conducted in the United States of America. The overall time to
      participate in this study was approximately 15.5 years. Participants were followed-up from
      January 1, 1997 up to June 30, 2012 for the assessment of cancer risk associated with
      pioglitazone use.
    
  